Nordea Investment Management AB Has $3.39 Million Stock Holdings in Waters Corporation $WAT

FierceBiotechGSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat

FierceBiotechCellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO

FierceBiotechBayer buys Perfuse in $2.4B deal for midphase eye disease prospect

Endpoints NewsCellCentric raises $220M to get multiple myeloma pill to market

FierceBiotechAfter a decade of hype, Najat Khan is bringing Recursion back down to earth

Endpoints NewsBayer to buy Perfuse Therapeutics for $300M upfront

FierceBiotechNovo CEO insists ‘no change in plan’ for CagriSema launch after single-chamber device ditched

FierceBiotechAvalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind

Endpoints NewsNovo Nordisk's Q1 in four words: Pills, pricing, payments and pressure

LabiotechSickle cell disease after Casgevy: seven companies to watch in 2026

FierceBiotechJ&J’s Ottava surgical robot meets primary endpoints in gastric bypass study

eLifeHER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content